

Clevertgene receives PCPNDT licence for prenatal genetic tests

26 April 2022 | News

Expands portfolio of tests to include Non-invasive prenatal genetic tests and preimplantation genetic screening



Clevertgene, a deep tech genomics company offering genetic diagnosis and discovery genomics solutions, received the PCPNDT (Pre-Conception and Pre-Natal Diagnostic Techniques) license and will be offering prenatal diagnostics and preimplantation genetic screening tests.

With this certification Clevertgene through its clinical diagnostics vertical The Gene Lab is launching a host of genetic tests that will improve outcomes for expectant parents and those planning a baby; these include Non-Invasive Prenatal Testing (NIPT) for detecting chromosomal aneuploidy in foetuses, preimplantation genetic screening, Products of Conception (POC) genetic testing as well as genetic counselling services.

Recently Clevertgene had augmented its capacity with the installation of the latest Illumina NovaSeq 6000 DNA sequencing platform. The introduction of these tests bolsters the existing suite of postnatal genetic diagnostics tests by The Gene Lab for inherited diseases as well as cancer. The NIPT tests will be able to examine cell-free DNA found in maternal blood originating from the foetus to screen for chromosome abnormalities, including Down syndrome, Edwards syndrome, Patau syndrome, and triploidy. The screening test can be performed as early as nine weeks of gestation and there is no risk to the foetus.